An in vitro pharmacogenomic approach reveals subtype-specific therapeutic vulnerabilities in atypical teratoid/rhabdoid tumors (AT/RT)
David Pauck(Düsseldorf University Hospital), Marc Remke(Saarland University)
Cited by 7
Related Papers
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650
Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma
|Journal of Clinical Oncology|2013|488